Excerpt from Wall Street Journal VC Daily Re-Vana, Boehringer Strike Deal for Gentler Eye-Disease Treatments By Brian Gormley, WSJ Pro Good day. Eye injections are a fact of life for many patients with severe ocular diseases. In a new partnership, Re-Vana...
The partnership strengthens the University’s reputation as a leading UK university for commercialisation of research and nurturing spin-outs capable of global impact. A spin-out from Queen's University – Re-Vana Therapeutics – has signed a major collaboration deal...
Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana...
RE-Vana Therapeutics CEO Michael J. O'Rourke announces two new team appointments: Following our successful $11.9M Series A in November 2022, Re-Vana Therapeutics is delighted to further strengthen our team with two new appointments as we develop our sustained release...
Visionary Ventures Leads Financing Round to Support the Development of Sustained Release Ophthalmic Therapeutics BELFAST, Northern Ireland, Nov. 30, 2022 /PRNewswire/ -- Re-Vana Therapeutics Ltd, a privately-held specialty drug delivery company...
Next up we have the Business Innovation Award, sponsored by Belfast City Council. The winner is Re Vana Therapeutics for their outstanding work on the treatment of chronic eye diseases. @re_vana @belfastcc#BelfastBusinessAwards...
Re-Vana Therapeutics win the "Retina Innovation Award' in Drug Delivery at the OIS Retina Summit - New York 13th July 2022 https://ois.net/ois-retina-innovation-summit-2022/ Michael O'Rourke pictured with the the ExSight Ventures team - Firas Rahhal M.D.,...
The OIS Drug Delivery Forum was held virtually on December 2, 2021. Re-Vana CEO Michael O'Rourke delivered a virtual presentation about the Re-Vana technology. See the video on Vimeo by following this link, or watch it embedded below....
The purpose of article series from AdLib, ‘Product | People | Potential’ is to feature and showcase the very best UK start-ups with great potential, truly inspiring businesses that are shaking up their sector. We capture and share the stories behind the name. We...
In the first 2 articles of the Retina Times Innovation and Entrepreneurship section, we discussed how to secure your intellectual property (IP), define your business model, assemble your team, and develop a quality management system (QMS). Here, we discuss fund...
Sophie Bakri MD, Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN joins Re-Vana Scientific Advisory Board